A common practitioner mistake: treating a female patient's irregular cycles, elevated androgens, or infertility as a purely gynecological problem without evaluating metabolic function. Insulin resistance is one of the most underappreciated drivers of hormonal imbalance in women, and the mechanism is direct. The Kharrazian Institute teaches practitioners to evaluate the metabolic-endocrine axis as a clinical priority — because when insulin signaling breaks down, female hormone physiology follows.
Understanding exactly how insulin resistance disrupts hormonal balance requires looking at the receptor level, the ovarian response, and the downstream cascade that connects blood sugar dysregulation to conditions like PCOS, androgen excess, and menstrual irregularity.
How Insulin Resistance Creates Hormonal Imbalance
When insulin receptors become less responsive, the pancreas compensates by secreting more insulin. The result is chronic hyperinsulinemia — elevated circulating insulin even when blood glucose appears controlled. Most practitioners understand this part. What gets missed is what that excess insulin does to ovarian tissue.
The ovaries express insulin receptors. Under normal insulin signaling, those receptors help regulate steroidogenesis appropriately. Under hyperinsulinemic conditions, the ovaries interpret the elevated insulin as a signal to increase androgen production — primarily testosterone and androstenedione. This is not a subtle effect. Research in reproductive endocrinology has established this as a primary mechanism behind androgen excess in women with insulin resistance, independent of whether the patient presents as overweight or has a formal diabetes diagnosis.
Dr. Kharrazian's clinical training emphasizes that this mechanism means a female patient's androgen excess is a metabolic problem first, not just a hormonal one. Treating the hormones without addressing insulin signaling is treating the symptom while leaving the driver intact.
The PCOS-Metabolic Connection: Why Blood Sugar Is the Starting Point
Polycystic ovary syndrome is the most visible expression of insulin-driven hormonal imbalance in women, and metabolic dysfunction sits at its core for the majority of affected patients. Research in endocrinology consistently demonstrates that hyperinsulinemia directly stimulates ovarian theca cells to overproduce androgens, disrupts follicular development, and contributes to the anovulatory cycles that define the condition clinically.
The follicular disruption piece matters for how practitioners explain this to patients. Elevated insulin impairs the normal maturation and release of follicles, which is why multiple small, undeveloped follicles appear on imaging. The cysts are not the cause — they are the evidence of a follicular development process that stalled due to hormonal dysregulation driven by insulin.
Beyond PCOS, the same insulin-androgen pathway contributes to hirsutism, acne, and menstrual irregularity in women who do not meet the full diagnostic criteria for PCOS. The practitioner who evaluates fasting insulin, fasting glucose, and a two-hour postprandial glucose challenge in every female patient presenting with these symptoms is practicing at a higher clinical standard than the practitioner who runs a standard hormone panel alone.
Cortisol, Adipose Tissue, and the Amplification Loop
Insulin resistance does not operate in isolation. The metabolic disruption it creates interacts with adrenal and adipose tissue function in ways that compound the hormonal imbalance.
Chronically elevated insulin promotes fat storage, particularly visceral adiposity. Visceral adipose tissue is metabolically active — it produces estrogens through peripheral aromatization of androgens, elevates inflammatory cytokines that impair insulin receptor function further, and contributes to HPA axis dysregulation. The result is an amplification loop: insulin resistance increases androgen production, androgens promote central fat storage, central fat storage worsens insulin resistance and adds excess estrogen from aromatization, and the disrupted HPA axis elevates cortisol, which further impairs insulin sensitivity.
Dr. Kharrazian's coursework teaches practitioners to map this loop explicitly when evaluating complex female endocrine cases. A patient presenting with weight gain, irregular cycles, fatigue, and mood instability may have all four components of this loop active simultaneously. Addressing only one point without recognizing the others explains why so many of these patients do not recover on single-target interventions.
Insulin's Effect on Sex Hormone-Binding Globulin
Hyperinsulinemia suppresses hepatic production of sex hormone-binding globulin (SHBG). This is a direct liver-mediated effect. SHBG is the protein that binds circulating sex hormones, keeping them in an inactive, bound state. When SHBG drops, free testosterone and free estrogen both rise — meaning the patient's androgen excess is amplified not only by increased production but by decreased binding capacity.
This is why a female patient's total testosterone can appear within reference range while her free testosterone is significantly elevated. Running only a total testosterone without measuring free testosterone or SHBG provides an incomplete picture. More importantly, low SHBG on a lab panel is a direct metabolic signal. Research in metabolic endocrinology has established SHBG as one of the more reliable surrogate markers for insulin resistance in women — a fact that makes it a clinically useful data point even before fasting insulin results are available.
Dr. Kharrazian's clinical training addresses SHBG as a cross-system marker, connecting liver function, insulin signaling, and sex hormone availability in a single reference point that too many practitioners overlook.
Puberty, Menstrual Development, and Early Metabolic Dysfunction
The reproductive consequences of insulin resistance are not limited to adult women. Research in pediatric endocrinology demonstrates that insulin resistance in adolescent females is associated with early or abnormal puberty development, premature adrenarche, and the early emergence of PCOS-like patterns. The clinical implication is that hormonal symptoms presenting at or shortly after puberty warrant metabolic evaluation, not just a gynecological workup.
Adolescent patients presenting with irregular cycles from the onset of menstruation, acne that does not resolve, or signs of androgen excess should have fasting insulin assessed as a matter of clinical course. Identifying insulin resistance early creates the opportunity to intervene before the full hormonal cascade has become entrenched.
Clinical Evaluation: What to Measure and Why
Standard hormone panels tell an incomplete story in patients where insulin resistance is the underlying driver. The following markers, assessed together, provide the clinical picture needed to identify the metabolic-endocrine connection:
- Fasting insulin: More sensitive than fasting glucose for early insulin resistance. Optimal range is 2–5 µIU/mL; values above 10 µIU/mL indicate significant resistance even when fasting glucose is normal.
- Two-hour postprandial glucose: Captures dysregulation that fasting glucose misses entirely in early-stage insulin resistance.
- SHBG: Low SHBG in women is a reliable surrogate marker for hyperinsulinemia. Below 70 nmol/L in reproductive-age women warrants investigation.
- Free testosterone: Elevated free testosterone in the presence of normal total testosterone points to suppressed SHBG and, by extension, hyperinsulinemia.
- HbA1c: Useful for trend monitoring but not sensitive enough for early detection. Use alongside fasting insulin, not as a replacement.
The sequence of thought Dr. Kharrazian's coursework teaches is to run the metabolic markers first, contextualize the hormone panel within those findings, and build the clinical strategy from the metabolic root outward. Practitioners who work in the opposite direction — treating hormones while ignoring metabolic drivers — routinely encounter patients who plateau or relapse.
Key Takeaways
- Hyperinsulinemia directly stimulates ovarian androgen production, making insulin resistance a primary driver of androgen excess in women.
- Low SHBG is a reliable surrogate marker for hyperinsulinemia and indicates elevated free sex hormone availability even when total values appear normal.
- The insulin-androgen-adipose-cortisol loop creates a self-reinforcing cycle that requires multi-point clinical intervention.
- Fasting insulin and postprandial glucose are more sensitive early indicators of insulin resistance than fasting glucose or HbA1c alone.
- Adolescent females presenting with hormonal symptoms warrant metabolic evaluation — early intervention is significantly more effective than late-stage correction.
Frequently Asked Questions
Yes. Insulin resistance occurs in lean individuals, particularly those with high refined carbohydrate intake, sedentary patterns, or genetic predisposition. Normal body weight does not rule out hyperinsulinemia. Fasting insulin testing is the only reliable way to identify it.
Elevated circulating insulin stimulates ovarian theca cells to overproduce androgens, impairs normal follicular maturation, and suppresses SHBG, amplifying free androgen availability. The combination disrupts ovulation and produces the hormonal pattern characteristic of PCOS.
Research in metabolic endocrinology supports SHBG as a surrogate marker for hyperinsulinemia in women. It is not a direct insulin measurement but is useful as a cross-system indicator, particularly when combined with fasting insulin and free testosterone values.
Functional medicine literature places optimal fasting insulin between 2–5 µIU/mL. Values above 10 µIU/mL suggest clinically significant resistance. Standard lab reference ranges are often too broad to catch early-stage dysfunction.
Research in pediatric endocrinology supports early metabolic evaluation in adolescents presenting with menstrual irregularity, acne, or signs of androgen excess. Fasting insulin is a low-cost, high-yield starting point that is frequently omitted in standard gynecological workups.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital's Department of Neurology specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. He is a Fellow of the American College of Nutrition, a Diplomate of the Board of Nutrition Specialists, a member of the American Association of Immunologists, and a Fellow of the Royal Society of Medicine (UK). The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Advance Your Clinical Training in Metabolic and Endocrine Dysfunction
The Kharrazian Institute offers evidence-based practitioner training in metabolic endocrinology, including clinical strategies for identifying and addressing insulin-driven hormonal imbalance in women. Visit the KI course library to review current offerings.
